Publications
539 results found
Limongelli P, Pai M, Bansi D, et al., 2007, Correlation between preoperative biliary drainage, bile duct contamination and postoperative outcomes for pancreatic surgery, Surgery
Ayav A, Navarra G, Basaglia E, et al., 2007, Results of major hepatectomy without vascular clamping using radiofrequency-assisted technique compared with total vascular exclusion, HEPATO-GASTROENTEROLOGY, Vol: 54, Pages: 806-809, ISSN: 0172-6390
- Author Web Link
- Cite
- Citations: 2
Bachellier P, Ayav A, Pai M, et al., 2007, Laparoscopic liver resection assisted with radiofrequency, AMERICAN JOURNAL OF SURGERY, Vol: 193, Pages: 427-430, ISSN: 0002-9610
- Author Web Link
- Cite
- Citations: 24
Mulier S, Ni Y, Frich L, et al., 2007, Experimental and clinical radiofrequency ablation: Proposal for standardized description of coagulation size and geometry, ANNALS OF SURGICAL ONCOLOGY, Vol: 14, Pages: 1381-1396, ISSN: 1068-9265
- Author Web Link
- Cite
- Citations: 53
Damrah OM, Lauretta A, Thillinianagram A, et al., 2007, Management of benign biliary strictures: Endoscopy versus surgery, institutional experience, Annual Meeting of the British-Society-of-Gastroenterology, Publisher: B M J PUBLISHING GROUP, Pages: A88-A88, ISSN: 0017-5749
East JE, Troup S, Mawdsley J, et al., 2007, Vascular endothelial growth factor and calprotectin in blood and bile for diagnosis of pancreatobiliary carcinoma: A pilot study, Annual Meeting of the British-Society-of-Gastroenterology, Publisher: B M J PUBLISHING GROUP, Pages: A75-A75, ISSN: 0017-5749
Habib N, Levičar NY, Gordon M, et al., 2007, Stem Cell Repair and Regeneration Volume 2, Publisher: World Scientific, ISBN: 9781908979421
This second book in the Stem Cell Repair and Regeneration series provides a deeper exploration of the therapeutic potential of undifferentiated human stem cells.Regenerative medicine is an extremely fast-moving field which is evolving from ...
Ayav A, Bachellier P, Habib NA, et al., 2007, Impact of radiofrequency assisted hepatectomy for reduction of transfusion requirements, AMERICAN JOURNAL OF SURGERY, Vol: 193, Pages: 143-148, ISSN: 0002-9610
- Author Web Link
- Cite
- Citations: 37
Stavrou GA, Tzias Z, von Falck C, et al., 2007, Hepatic resection using heat coagulative necrosis. First report of successful trisegmentectomy after hypertrophy induction, LANGENBECKS ARCHIVES OF SURGERY, Vol: 392, Pages: 95-97, ISSN: 1435-2443
- Author Web Link
- Cite
- Citations: 6
Szyszko T, AL-Nahhas A, Canelo R, et al., 2007, Assessment of response to treatment of unresectable liver tumours with <SUP>90</SUP>Y microspheres:: Value of FDG PET versus computed tomography, NUCLEAR MEDICINE COMMUNICATIONS, Vol: 28, Pages: 15-20, ISSN: 0143-3636
- Author Web Link
- Cite
- Citations: 67
Szyszko T, AL-Nahhas A, Tait P, et al., 2007, Management and prevention of adverse effects related to treatment of liver tumours with <SUP>90</SUP>Y microspheres, NUCLEAR MEDICINE COMMUNICATIONS, Vol: 28, Pages: 21-24, ISSN: 0143-3636
- Author Web Link
- Cite
- Citations: 29
Habib N, Levicar N, Dimarakis I, et al., 2007, Stem cells as a treatment for chronic liver disease and diabetes, Handbook of Experimental Pharmacology, Pages: 243-262
Habib N, Pai M, Canelo R, 2007, Haemostasis in Liver Surgery, Haemostasis in Surgery, Editors: Hakim, Canelo, Publisher: Imperial College London, ISBN: 978-1-86094-691-2
Habib NA, Levicar N, Gordon M, et al., 2007, Stem Cell Repair and Regeneration, London, Publisher: Imperial College
Ayav A, Jiao LR, Habib NA, 2007, Bloodless liver resection using radiofrequency energy, DIGESTIVE SURGERY, Vol: 24, Pages: 314-317, ISSN: 0253-4886
- Author Web Link
- Cite
- Citations: 35
Harrop R, Drury N, Shingler W, et al., 2007, Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces immune responses., Clinical Cancer Research, Vol: 13, Pages: 4487-4494
Jiao RL, Habib NA, 2007, Radiofrequency Assisted Liver Resection, Liver Surgery, Editors: Fan, HK
Diao Y, Ma J, Xiao WD, et al., 2007, Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistain., World J Gastroenterology, Vol: 13, Pages: 4615-4619
Levicar N, Dimarakis I, Flores C, et al., 2007, Stem cells as a treatment for chronic liver disease and diabetes., Handb Exp Pharmacol, Pages: 243-262, ISSN: 0171-2004
Advances in stem cell biology and the discovery of pluripotent stem cells have made the prospect of cell therapy and tissue regeneration a clinical reality. Cell therapies hold great promise to repair, restore, replace or regenerate affected organs and may perform better than any pharmacological or mechanical device. There is an accumulating body of evidence supporting the contribution of adult stem cells, in particular those of bone marrow origin, to liver and pancreatic islet cell regeneration. In this review, we will focus on the cell therapy for the diseased liver and pancreas by adult haematopoietic stem cells, as well as their possible contribution and application to tissue regeneration. Furthermore, recent progress in the generation, culture and targeted differentiation of human haematopoietic stem cells to hepatic and pancreatic lineages will be discussed. We will also explore the possibility that stem cell technology may lead to the development of clinical modalities for human liver disease and diabetes.
Ferko A, Lesko M, Subrt Z, et al., 2006, A modified radiofrequency-assisted approach to right hemihepatectomy, EJSO, Vol: 32, Pages: 1209-1211, ISSN: 0748-7983
- Author Web Link
- Cite
- Citations: 15
Habib N, Canelo R, 2006, Liver and Pancreatic Diseases Management, Publisher: Springer Science & Business Media, ISBN: 9780387295121
The aim of this book is to present a unique compilation of lectures given by international speakers at the Hammersmith Hospital during the recent Meetings in Hepato-Pancreato-Biliary and Transplantation.
Helmy S, Salama H, Mawdsley J, et al., 2006, The effect of oral methylene blue on viral load in chronic hepatitis C infection: an open-label pilot study, LIVER INTERNATIONAL, Vol: 26, Pages: 72-72, ISSN: 1478-3223
Dimarakis I, Levicar N, Nihoyannopoulos P, et al., 2006, In vitro stem cell differentiation into cardiomyocytes. Part 1. Culture medium and growth factors, Journal of Cardiothoracic-Renal Research, Vol: 1, Pages: 107-114, ISSN: 1574-0668
Recent developments in the field of regenerative stem cell therapy for ischaemic heart disease have lead to an explosion in the clinical trial realm. At present no consensus exists regarding, amongst others, the optimal cell type as well as the underlying mechanism of action for any clinical improvement observed. As de novo reconstitution of myocardial tissue from multipotent stem cells is one of the working theories, the transdifferentiation potential of cellular populations under investigation into cardiomyocyte lineage phenotypes must ideally be assessed in preclinical bench work. Culture medium composition and a variety of growth factors are crucial determinants in this process. We discuss all relevant data acquired from in vitro work. © 2006 Asian-Pacific Cardiothoracic-Renal Association (APCRA).
Dimarakis I, Levicar N, Nihoyannopoulos P, et al., 2006, In vitro stem cell differentiation into cardiomyocytes. Part 2: Chemicals, extracellular matrix, physical stimuli and coculture assays, Journal of Cardiothoracic-Renal Research, Vol: 1, Pages: 115-121, ISSN: 1574-0668
Encouraged by the initial in vivo and clinical data on cardiac stem cell transplantation, the number of conducted clinical studies has increased exponentially. Pre-transplantation differentiation may provide, beyond proof of principal, more efficient cellular repopulation. This review concerns parameters implicated in transdifferentiation in vitro, besides cell medium composition and cytokines/growth factors. These include various chemicals, extracellular matrix cues, coculture assays and physical stimuli. Identification of all determinants in this process and possible interactions will augment in developing efficient protocols for targeted stem cell differentiation towards the cardiomyocyte lineage prior to transplantation. © 2006 Asian-Pacific Cardiothoracic-Renal Association (APCRA).
Szyszko T, Nadarajah J, Khan S, et al., 2006, Yttrium 90 microspheres in the treatment of hepatic metastases: a comparison of FDG-PET and CT imaging in assessment of response to treatment, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 33, Pages: S327-S327, ISSN: 1619-7070
Jiao LR, Tierris I, Ayav A, et al., 2006, A new technique for spleen preservation with radiofrequency, SURGERY, Vol: 140, Pages: 464-466, ISSN: 0039-6060
- Author Web Link
- Cite
- Citations: 16
Jiao LR, Habib NA, 2006, Randomized clinical trial of the effects of abdominal drainage after elective hepatectomy using the crushing clamp method (<i>Br J Surg</i> 2006; 93: 422-426), BRITISH JOURNAL OF SURGERY, Vol: 93, Pages: 1024-1025, ISSN: 0007-1323
- Author Web Link
- Cite
- Citations: 3
Gordon MY, Levicar N, Pai M, et al., 2006, Characterization and clinical application of human CD34<SUP>+</SUP> stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor, STEM CELLS, Vol: 24, Pages: 1822-1830, ISSN: 1066-5099
- Author Web Link
- Cite
- Citations: 213
Harrop R, Hawkins R, Anthoney A, et al., 2006, Open label phase II studies of modified vaccinia ankara expressing the tumor antigen 5T4 given in conjunction with IFL and FOLFOX chemotherapy regimens: Final analysis of safety and immunogenicity of MVA 5T4 given before, during and after chemotherapy., 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 106S-106S, ISSN: 0732-183X
Harrop R, Hawkins R, Anthoney A, et al., 2006, Open label phase II studies of modified vaccinia ankara expressing the tumor antigen 5T4 given in conjunction with IFL and FOLFOX chemotherapy regimens: Final analysis of safety and immunogenicity of MVA 5T4 given before, during and after chemotherapy., J Clin Oncol, Vol: 24
2527 Background: 5T4 is a tumour associated antigen that is widely expressed on the surface of most human adenocarcinomas, including colorectal, but rarely in normal cells. Modified Vaccinia Ankara (MVA) has been employed as a vaccine vector to deliver 5T4. Previously, MVA-5T4 has been evaluated in a phase I/II clinical trial in stage IV colorectal cancer patients. MVA-5T4 was shown to be safe and well tolerated and induced 5T4 specific immune responses in most patients. Furthermore, 5T4 specific antibody titres correlated with clinical benefit. METHODS: Two open label phase II clinical trials were initiated in which patients with advanced colorectal cancer received MVA-5T4 in conjunction with either 5-FU/leukovorin and irinotecan (TV2-IFL; n=19 patients) or 5-FU/leukovorin and oxaliplatin (TV2-FOLFOX; n=17 patients). MVA-5T4 was administered up to 6 times, 2 prior to, 2 during and 2 post-chemotherapy. The primary objectives were to assess the safety and immunogenicity of MVA-5T4 given in combination with chemotherapy. RESULTS: Recruitment to both trials is complete and MVA-5T4 was well tolerated in all ITT patients, with no serious adverse events being associated with MVA-5T4. 5T4-specific cellular and humoral immune responses were monitored before, during and after chemotherapy in all 23 per protocol patients (n=12 for TV2-IFL and n=11 for TV2-FOLFOX). Following vaccination, all 23 patients mounted 5T4 cellular and/or humoral responses. Immune responses were detectable during chemotherapy in the majority of patients. IFNγ ELISPOT responses to 5T4 peptides revealed precursor frequencies as high as 1 in 1000 PBMCs. Assessment of clinical responses in all PP patients demonstrated an overall response rate of 65% across both trials. CONCLUSIONS: MVA-5T4 is safe and well tolerated when administered in conjunction with IFL and FOLFOX chemotherapy regimens. Furthermore, 5T4 specific immune responses are induced in all per protocol patients and can be boosted or main
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.